Sectors

Pharmaceutical firms’ interest in AI brings shift in property requirements

Many R&D firms are moving from traditional lab spaces to premises that offer sufficient power and network capabilities.

JLL: Investment appetite for life sciences enters new phase

Equity investors and lenders increasingly look to the UK and continental European life sciences sector as the market continues to mature, say Chris Walters and Brad Greenway at JLL.

Understanding occupier trends vital for life sciences’ future

High supply means life sciences tenants can call the shots, so meeting evolving user needs is paramount for investors.

The future is bright for life sciences property

In 2024, market vacancies increased with new construction delivered vacant, but this trend should reverse as demand and supply return to more manageable levels.

Life sciences sees signs of recovery

Venture capital funding is rebounding, which is driving rental growth.

Investment appetite remains for life sciences real estate

Year-on-year sales volume for lab, R&D space has continued to fall, but a turnaround is expected.

Offices are coming out of exile

A spate of trophy deals in the last week signals institutions are warming up to the beleaguered asset class.

Aware Super’s UK platform to capture ‘window of opportunity’ in offices

The investor’s newly formed international team has partnered with Delancey to invest £1bn in the UK, with London offices as the initial focus.

Nuveen’s Asia core fund buys first Korean office

The firm has acquired three offices under the core strategy in Singapore, Sydney and Seoul since it was launched in 2018.

MSCI: Distress pressure is building across global real estate

Property-level distress is not just a US office problem, says Tom Leahy, MSCI’s head of EMEA real assets research.